£3.5m Seed Round for Cytoseek

Another EBS alumni to thrive following 12 months intensive training with EBS has been Dr Ben Carter. Ben is a founder and COO of Cytoseek Ltd., a spinout from University of Bristol, developing technology that will allow a whole new range of cancers to be effectively targeted with immunotherapy

The company has raised £3.5 million ($4.87 million) from investors to continue to test its technology and to develop commercial partnerships. While the technology is still three to four years from being ready for human clinical trials, it has shown promise in initial lab tests. 

The funding round represents the debut investment for a new Bristol-based venture capital firm called Science Creates Ventures (SCV) that is focused on deep tech companies undertaking cutting-edge innovations in computer science and biotechnology. 

Related posts

Funding for alternative to animal testing

A near-£1 million investment will help University of Dundee spinout company Ten Bio Ltd to commercialise the human skin culture system it developed to provide a viable alternative for many experiments currently performed on animals. EBS provided advice and support […]

Supplant announces $24m investment

We’re delighted to learn that EBS alumni Dr Tom Simmons and his company Supplant Inc., have just closed a series-A venture capital financing round to commercialise their low-cost sugar replacement made from plant fibre. The company, started in 2017 after […]